Intermittent PI3Ko inhibition sustains anti-tumor immunity and curbs irAEs

View/ Open
eschweiler_et_al_2022 (12.87Mb)
Download
Publication date
2022-05-26Author
Eschweiler, S.Ramirez-Suastegui, C.
Li, Y.
King, E.
Chudley, L.
Thomas, J.
Wood, O.
von Witzleben, A.
Jeffrey, D.
McCann, K.
Simon, H.
Mondal, M.
Wang, A.
Dicker, M.
Lopez-Guadamillas, E.
Chou, T.-F.
Dobbs, N.A.
Essame, L.
Acton, G.
Kelly, F.
Halbert, G.
Sacco, J.J.
Schache, A.G.
Shaw, R.
McCaul, J.A.
Paterson, C.
Davies, J.H.
Brennan, Peter A.
Singh, R.P.
Loadman, Paul M.
Wilson, W.
Hackshaw, A.
Seumois, G.
Okkenhaug, K.
Thomas, G.J.
Jones, T.M.
Ay, F.
Friberg, G.
Kronenberg, M.
Vanhaesebroeck, B.
Vijayananad, P.
Ottensmeier, C.H.
Keyword
PI3Kδ inhibitionAMG319
Head and neck surgery
Immunotherapy
Research Development Fund Publication Prize Award
Rights
(c) 2022 The Authors. This is an Open Access article distributed under the Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/)Peer-Reviewed
YesOpen Access status
openAccess